e-learning
resources
Madrid 2019
Wednesday, 02.10.2019
Rare and ultra-rare diseases and the lungs: updates and new perspectives
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Late Breaking Abstract - Rituximab limits the progression of fibrosing mediastinitis
C. Varghese (Rochester, United States of America), G. Johnson (Rochester, United States of America), P. Eiken (Rochester, United States of America), P. Tobias (Rochester, United States of America)
Source:
International Congress 2019 – Rare and ultra-rare diseases and the lungs: updates and new perspectives
Session:
Rare and ultra-rare diseases and the lungs: updates and new perspectives
Session type:
Oral Presentation
Number:
5325
Disease area:
Interstitial lung diseases, Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Varghese (Rochester, United States of America), G. Johnson (Rochester, United States of America), P. Eiken (Rochester, United States of America), P. Tobias (Rochester, United States of America). Late Breaking Abstract - Rituximab limits the progression of fibrosing mediastinitis. 5325
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Optimizing invasive ventilation for SMA type 1 children who are receiving the gene therapy
Related content which might interest you:
Late Breaking Abstract - Use of mepolizumab in bronchiectasis with underlying eosinophilic condition
Source: International Congress 2018 – New methods for diagnosing and treating lung diseases
Year: 2018
Late Breaking Abstract - Treatment with ATYR1923 reduces biomarkers in COVID-19 pneumonia
Source: Virtual Congress 2021 – Diagnosis and management of COVID-19
Year: 2021
Late Breaking Abstract - Acute multi-organ symptoms predict long COVID
Source: Virtual Congress 2021 – Diagnosis and management of COVID-19
Year: 2021
Late Breaking Abstract - Fully automated airway measurement correlates with radiological disease progression in Idiopathic Pulmonary Fibrosis
Source: Virtual Congress 2021 – Remote monitoring of respiratory patients
Year: 2021
Late Breaking Abstract - Early response to benralizumab in Canadians with severe eosinophilic asthma
Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies
Year: 2021
Late Breaking Abstract - Systemic ferritin is an early disease biomarker for silicosis patients
Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases
Year: 2021
Late Breaking Abstract - Promising results of the infliximab biosimilar Inflectra® in severe sarcoidosis patients
Source: International Congress 2017 – The many faces of sarcoidosis
Year: 2017
Late Breaking Abstract - Plasma cells and endothelitis in COVID-19 lung pathology
Source: Virtual Congress 2020 – Covering COVID - the best abstracts
Year: 2020
Late Breaking Abstract - Frequency and characteristics of TB relapses
Source: International Congress 2017 – Late-breaking studies in pulmonary diseases
Year: 2017
Late Breaking Abstract - Mepolizumab reduces exacerbations in eosinophilic COPD
Source: International Congress 2017 – Late-breaking studies in asthma and COPD
Year: 2017
Late Breaking Abstract - Increased risk of pulmonary embolism in patients with radiological severe COVID-19 pneumonia
Source: Virtual Congress 2020 – COVID-19 clinical studies
Year: 2020
Late Breaking Abstract - Defining a severe asthma super-responder: findings from a Delphi process
Source: Virtual Congress 2020 – Advances in asthma treatment
Year: 2020
Late Breaking Abstract - Asthma control in preschool and subsequent disease remission
Source: International Congress 2019 – Asthma and the world
Year: 2019
Late Breaking Abstract - Clinical characteristics and lung function trends of severe eosinophilic asthma patients unresponsive to Mepolizumab
Source: International Congress 2019 – Blood eosinophils and more in airway diseases
Year: 2019
Late Breaking Abstract - Phase II trial of pirfenidone in patients with progressive fibrosing unclassifiable ILD (uILD)
Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Interstitial lung diseases and pulmonary hypertension
Year: 2019
Late Breaking Abstract - Survival and course of lung function in patients with idiopathic pulmonary fibrosis with or without antifibrotic treatment: long-term results of the INSIGHTS-IPF registry
Source: International Congress 2019 – Idiopathic pulmonary fibrosis and surroundings
Year: 2019
Late Breaking Abstract - Value of the interleukin profile can be an objective standart for control the tactics of managing patients with bronchiolitis
Source: Virtual Congress 2021 – Respiratory infections
Year: 2021
Late Breaking Abstract - Air pollution and IPF acute exacerbation
Source: International Congress 2017 – The wide spectrum of ILDs
Year: 2017
Late Breaking Abstract - Study of natural autoantibodies in rheumatoid arthritis patients with pulmonary involvement
Source: International Congress 2017 – Late-breaking studies in pulmonary diseases
Year: 2017
B-lymphocyte targeted therapy for patients with progressive fibrosing mediastinitis
Source: International Congress 2014 – Modern approach and old dilemmas in lung diseases
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept